Company profile
Alkermes PLC logo

Alkermes PLC

Pipeline3 assets

  • Sodium oxybate extended-release oral suspensiononce-nightly extended-release oral suspension / Sleep disorders
    Idiopathic hypersomniaPhase 3Evaluating in REVITALYZ
  • Olanzapine and samidorphanLYBALVI / oral small molecule combination / Psychiatry
    Schizophrenia and bipolar I disorder (pediatric)Phase 3Evaluating in ENLIGHTEN-Youth
  • AlixorextonALKS 2680 / orexin 2 receptor / oral small molecule agonist / Sleep disorders
    Narcolepsy type 1Phase 3Brilliance Studies programNarcolepsy type 2Phase 3Brilliance Studies programIdiopathic hypersomniaPhase 2Vibrance-3

Latest news14 items

All news

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

— Company to Present 11 Posters Demonstrating Commitment to Advancing Innovative Research for People Living With Chronic Psychiatric and Neurological Disorders — DUBLIN --(BUSINESS WIRE)--May 26, 2026-- Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical and real-world data

Presentation / Abstract • Phase 2ASCP poster presentations Wed, May 27, 2026, 11:45 AM ET

Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

– Real-World Evidence of Positive Impact of LYBALVI ® (olanzapine and samidorphan) on Treatment Patterns and Rates of Relapse Among Patients with Schizophrenia or Bipolar I Disorder, Including Young Adults – – APA Plenary Presentation Highlights Recent Clinical Data, Including Results for Negative

Presentation / AbstractAPA Plenary presentation Sat, May 16, 2026

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

– LUMRYZ Met All Primary and Key Secondary Endpoints Demonstrating Statistically Significant and Clinically Meaningful Improvements Compared to Placebo in Excessive Daytime Sleepiness and Patient-Reported Disease Severity – – Safety Profile Consistent With Known Safety Profile of LUMRYZ – DUBLIN

Trial Results • Phase 3oral presentation Tue, May 12, 2026

Alkermes plc Reports First Quarter 2026 Financial Results

DUBLIN --(BUSINESS WIRE)--May 5, 2026-- Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended March 31, 2026 and financial expectations for full year 2026. To view the detailed first quarter 2026 earnings press release and presentation, please visit the company’s

Alkermes to Report First Quarter Financial Results on May 5, 2026

DUBLIN --(BUSINESS WIRE)--Apr. 21, 2026-- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST) on Tuesday, May 5, 2026 to discuss the company’s first quarter financial results. The webcast player and accompanying slides may be accessed on

Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting

— Alixorexton Data From Seven-Week Open-Label Extension Period Demonstrated Sustained Improvements in Patient-Reported Disease Severity, Cognitive Functioning and Fatigue— — Alixorexton Was Generally Well Tolerated at All Doses Tested — — Phase 3 Brilliance NT1 Study of Alixorexton in Patients With

Presentation / Abstract • Phase 2

Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program

— Competitive Grant Program to Offer Individual Grants of Up to $10,000 per Project — — Inaugural Application Cycle Open to Licensed Psychiatric-Mental Health Nurse Practitioners Across Multiple Clinical Settings — — Application Period to Run From March 16, 2026 Through June 1, 2026 — DUBLIN

Alkermes to Present at the Stifel 2026 Virtual CNS Forum

DUBLIN --(BUSINESS WIRE)--Mar. 10, 2026-- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:30 a.m. ET ( 12:30 p.m. GMT). The live webcast may be accessed under the Investors tab on

Alkermes plc Announces CEO Succession Plan

— Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes — — Board of Directors Appointed Blair Jackson, Alkermes’ Current Executive Vice President, Chief Operating Officer, as CEO Effective as of August 1, 2026 — — Richard Pops to Continue

Alkermes to Present at the TD Cowen 46th Annual Health Care Conference

DUBLIN --(BUSINESS WIRE)--Feb. 24, 2026-- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the TD Cowen 46 th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 a.m. ET ( 2:10 p.m. GMT). The live webcast may be accessed under the

Alkermes PLC • Endpoint Arena